Aardvark Therapeutics (NASDAQ:AARD) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen lowered shares of Aardvark Therapeutics (NASDAQ:AARD – Free Report) from a sell rating to a strong sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

A number of other research analysts also recently commented on AARD. BTIG Research dropped coverage on Aardvark Therapeutics in a research note on Monday, October 12th. They issued a “neutral” rating for the company. HC Wainwright reduced their price objective on shares of Aardvark Therapeutics from $4.00 to $2.00 and set a “hold” rating on the stock in a research note on Monday, October 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Tuesday, September 29th. UBS Group set a $4.00 target price on shares of Aardvark Therapeutics in a research report on Monday, October 19th. Finally, Royal Bank Of Canada set a $2.50 price target on shares of Aardvark Therapeutics in a report on Friday, October 23rd. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Aardvark Therapeutics has a consensus rating of “Hold” and a consensus price target of $11.06.

Get Our Latest Research Report on Aardvark Therapeutics

Aardvark Therapeutics Price Performance

Aardvark Therapeutics stock opened at $1.26 on Friday. The firm has a market cap of $27.57 million, a PE ratio of -0.38 and a beta of 4.38. The stock’s fifty day moving average price is $3.68 and its two-hundred day moving average price is $5.66. Aardvark Therapeutics has a one year low of $0.93 and a one year high of $16.60.

Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.19). Sell-side analysts expect that Aardvark Therapeutics will post -3.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00. Following the completion of the transaction, the insider owned 35,475 shares of the company’s stock, valued at approximately $183,760.50. The trade was a 63.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 17.80% of the company’s stock.

Hedge Funds Weigh In On Aardvark Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Aardvark Therapeutics during the second quarter worth $1,077,000. Marshall Wace LLP grew its stake in shares of Aardvark Therapeutics by 593.0% in the third quarter. Marshall Wace LLP now owns 132,204 shares of the company’s stock worth $697,000 after purchasing an additional 113,128 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Aardvark Therapeutics in the first quarter worth $267,000. J. Goldman & Co LP acquired a new stake in Aardvark Therapeutics in the second quarter valued at $233,000. Finally, Ieq Capital LLC acquired a new stake in Aardvark Therapeutics in the second quarter valued at $221,000.

Aardvark Therapeutics Company Profile

(Get Free Report)

Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.

See Also

Analyst Recommendations for Aardvark Therapeutics (NASDAQ:AARD)

Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.